Search results
25 lis 2013 · PDF. Tools. Share. Abstract. The purpose of this report was to provide consensus recommendations for the use of immunosuppressive therapy in dogs with active glomerular diseases.
17 paź 2023 · Adult cats with PU/PD warrant assessment of a total T4 (thyroxine) test, and adult dogs with PU/PD warrant testing for hyperadrenocorticism (e.g., adrenocorticotropic hormone stimulation test, low-dose dexamethasone suppression test).
5 sie 2019 · Protein-losing enteropathy (PLE) because of chronic inflammatory enteropathy (CIE) in dogs is often treated with a combination of glucocorticoids and second-line immunosuppressant (SLI). This combined approach might not be necessary in all dogs.
Treatment of IMPA is significantly different than treatment of many other conditions that may present with similar clinical signs, and protocols may vary between patients. Therefore, making an accurate diagnosis is critical.
1 wrz 2024 · Acute-onset pancreatitis is a common disease in dogs and is associated with significant morbidity and even mortality. While the treatment of AP in the past has been primarily symptomatic and supportive, a new specific therapeutic agent, fuzapladib sodium, is now available in Japan and the US.
25 lis 2013 · An ACEi should be initial treatment for most dogs with proteinuria. The initial choice of drug and starting dose may vary, but can be gradually increased to achieve a therapeutic target. The ideal therapeutic target is a reduction in the UPC to <0.5 without inappropriate worsening of renal function.
Of the 44 dogs in the study, 5 dogs (11%) received telmisartan combined with benazepril. At the 1‐month follow‐up, 1 dog had a complete response, 1 had a partial response, and 3 (60%) had no response. The mean ± SD UPC pretreatment was 3.62 ± 1.72 compared to 2.5 ± 1.35 at 1 month post‐treatment (31% decrease).
